 |
PDBsum entry 6ulh
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
376 a.a.
|
 |
|
|
|
|
|
|
|
145 a.a.
|
 |
|
|
|
|
|
|
|
76 a.a.
|
 |
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Legionella effector mavc targets the ube2n~ub conjugate for noncanonical ubiquitination.
|
 |
|
Authors
|
 |
K.Puvar,
S.Iyer,
J.Fu,
S.Kenny,
K.I.Negrón terón,
Z.Q.Luo,
P.S.Brzovic,
R.E.Klevit,
C.Das.
|
 |
|
Ref.
|
 |
Nat Commun, 2020,
11,
2365.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The bacterial effector MavC modulates the host immune response by blocking Ube2N
activity employing an E1-independent ubiquitin ligation, catalyzing formation of
a γ-glutamyl-ε-Lys (Gln40Ub-Lys92Ube2N) isopeptide
crosslink using a transglutaminase mechanism. Here we provide biochemical
evidence in support of MavC targeting the activated, thioester-linked
Ube2N~ubiquitin conjugate, catalyzing an intramolecular transglutamination
reaction, covalently crosslinking the Ube2N and Ub subunits effectively
inactivating the E2~Ub conjugate. Ubiquitin exhibits weak binding to MavC alone,
but shows an increase in affinity when tethered to Ube2N in a disulfide-linked
substrate that mimics the charged E2~Ub conjugate. Crystal structures of MavC in
complex with the substrate mimic and crosslinked product provide insights into
the reaction mechanism and underlying protein dynamics that favor transamidation
over deamidation, while revealing a crucial role for the structurally unique
insertion domain in substrate recognition. This work provides a structural basis
of ubiquitination by transglutamination and identifies this enzyme's true
physiological substrate.
|
 |
|
|
|
|
 |